Editor: 

POSITIVE

A unique opportunity to allow young women who have had hormone sensitive breast cancer to temporarily interrupt their treatment and try to conceive.

 

The POSITIVE academic study – which will involve 500 women under the age of 42 and 170 hospitals and breast cancer centres from 20 countries – aims to answer the question of whether women can interrupt their endocrine treatment to try to have a baby, without increasing the risk of cancer recurrence.

Content: 

About 15% of patients with breast cancer are diagnosed during their reproductive years and an estimated 100,000 women under 42 are diagnosed with hormone sensitive breast cancer every year.
These women are therefore treated with endocrine therapy, which blocks the natural production of hormones in order to reduce risks of recurrence. Endocrine therapy may be prescribed for 5-10 years and impacts the ovaries, preventing conception while on treatment.

However, women with breast cancer may not be able to wait so long before considering pregnancy.

Editor: 

Led under the BIG umbrella by the International Breast Cancer Study Group, POSITIVE represents a unique opportunity to allow young women who have had hormone sensitive breast cancer to temporarily interrupt their treatment and try to conceive.

It will improve our scientific understanding of issues related to conception and pregnancy in young women who have had breast cancer, especially by obtaining solid data about whether endocrine therapy can be interrupted without increasing the risk of breast cancer recurrence.